# Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma

> **NCT07154797** · NA · COMPLETED · sponsor: **SpyGlass Pharma, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Cataract
- Ocular Hypertension
- Glaucoma

## Interventions

- **COMBINATION_PRODUCT:** Bimatoprost Implant System / IOL Combination

## Key facts

- **NCT ID:** NCT07154797
- **Lead sponsor:** SpyGlass Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-21
- **Primary completion:** 2022-12-13
- **Final completion:** 2022-12-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07154797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07154797, "Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07154797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*